Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
29.5(c) 29.55(c) 29.45(c) 28.9(c) 29.1 Last
36 950 27 176 17 325 24 908 6 637 Volume
+3.51% +0.17% -0.34% -1.87% +0.69% Change
More quotes
Estimated financial data (e)
Sales 2019 - - -
Net income 2019 -66,0 M -7,63 M -7,63 M
Net cash position 2019 184 M 21,3 M 21,3 M
P/E ratio 2019 -7,79x
Yield 2019 -
Sales 2020 - - -
Net income 2020 -98,7 M -11,4 M -11,4 M
Net cash position 2020 183 M 21,1 M 21,1 M
P/E ratio 2020 -15,0x
Yield 2020 -
Capitalization 973 M 113 M 112 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 12
Free-Float 84,0%
More Financials
Company
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic... 
Sector
Biotechnology & Medical Research
Calendar
11/04 | 02:00amEarnings Release
More about the company
All news about ASCELIA PHARMA AB (PUBL)
09/21ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
09/21Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the..
CI
09/20ASCELIA PHARMA AB(OM : ACE) added to S&P Global BMI Index
CI
09/13Certain Ordinary Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending ..
CI
08/19QUARTERLY REPORT Q2 2021 : Preparing Oncoral for the next level
AQ
08/19Ascelia Pharma AB publ Announces Earnings Results for the Second Quarter Ended June 30,..
CI
08/18ASCELIA PHARMA : Covid-19 extends recruitment period of SPARKLE study
AQ
08/18Ascelia Pharma AB Announces That the Continued Global Impact of the Covid-19 Pandemic C..
CI
08/13ASCELIA PHARMA : Abstract for Orviglance comparison study to gadolinium accepted at the wo..
AQ
08/13Ascelia Pharma AB Announces Abstract for Orviglance Comparison Study to Gadolinium Acce..
CI
08/10ASCELIA PHARMA : receives conditional FDA acceptance for brand name Orviglance
AQ
08/10Ascelia Pharma AB Receives Conditional U.S. Food and Drug Administration Acceptance for..
CI
05/12QUARTERLY REPORT Q1 2021 : US office opened in preparation of launch
AQ
05/12Ascelia Pharma AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
05/05ASCELIA PHARMA : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 20..
AQ
More news
News in other languages on ASCELIA PHARMA AB (PUBL)

- No features available -

More news
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 28,90 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-48.76%113
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414